SCHEMBL4676508

SCHEMBL4676508

O=C(Cc1nc(Cc2ccccn2)cs1)C(=O)c1nn[nH]n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
GFER P55789 1/20 0.34
SLC40A1 Q9NP59 3/20 0.33
RAB9A P51151 2/20 0.33
FFAR2 O15552 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.32
GLS O94925 1/20 0.32
CES1 P23141 1/20 0.32
NCEH1 Q6PIU2 1/20 0.32
IDO1 P14902 1/20 0.32
POLB P06746 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671506 0.92 PDE5A (0.36) PDE5APDE1APDE1BPDE1CSMN1; SMN2
SCHEMBL4671627 0.86 HDAC1 (0.42) SMN1; SMN2ALDH1A1RAB9ANPC1LMNA
SCHEMBL4672374 0.84 SLC40A1 (0.36) PDE5APDE1APDE1BPDE1CSMN1; SMN2
SCHEMBL4677732 0.83 HDAC1 (0.32) SMN1; SMN2ALDH1A1MAPTHPGDGFER
SCHEMBL4673601 0.82 LMNA (0.36) PDE5ASMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL4672920 0.81 RAB9A (0.36) SMN1; SMN2MAPTRAB9AFFAR2NPC1
SCHEMBL4676479 0.80 RAB9A (0.35) SMN1; SMN2MAPTRAB9AFFAR2NPC1
SCHEMBL4674982 0.80 FFAR2 (0.35) PDE5APDE1APDE1BPDE1CSMN1; SMN2
SCHEMBL4675534 0.80 FFAR2 (0.35) SMN1; SMN2ALDH1A1HPGDFFAR2CES1
SCHEMBL4675014 0.80 HDAC1 (0.39) CES1NCEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PDE5A 4733/4885PDE1A 3932/4885PDE1B 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.